ASH Congress 2025

Oral presentation at ASH 2025 to feature pivotal Phase 3 results of Xervyteg® (MaaT013), including previously disclosed primary endpoint data (62% GI-ORR at Day 28) and new findings on secondary endpoints (data at Day 56 and 3 months, and duration of response). Results highlight strong efficacy and indicate a favorable safety profile for Xervyteg® (MaaT013), reinforcing its potential to become the first third-line treatment for patients with gastrointestinal aGvHD unresponsive to current therapi